These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 1802748)

  • 41. 1-Methyl-4-phenylpyridinium is a substrate of the vesicular monoamine uptake system of chromaffin granules.
    Scherman D; Darchen F; Desnos C; Henry JP
    Eur J Pharmacol; 1988 Feb; 146(2-3):359-60. PubMed ID: 3259507
    [No Abstract]   [Full Text] [Related]  

  • 42. Selective (+)-amphetamine neurotoxicity on striatal dopamine nerve terminals in the mouse.
    Jonsson G; Nwanze E
    Br J Pharmacol; 1982 Oct; 77(2):335-45. PubMed ID: 7139192
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evidence for the release of 1-methyl-4-phenylpyridinium (MPP+) from rat striatal neurons in vitro.
    Keller HH; Da Prada M
    Eur J Pharmacol; 1985 Dec; 119(3):247-50. PubMed ID: 3879221
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neuroblastic apoptosis in the subventricular zone is caused by 1-methy-4-phenylpiridinium (MPP(+)) converted from MPTP through MAO-B.
    Ito T; Suzuki K; Uchida K; Nakayama H
    Exp Toxicol Pathol; 2012 Nov; 64(7-8):761-5. PubMed ID: 21324658
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sensitive and selective liquid chromatography/tandem mass spectrometry methods for quantitative analysis of 1-methyl-4-phenyl pyridinium (MPP+) in mouse striatal tissue.
    Zhang MY; Kagan N; Sung ML; Zaleska MM; Monaghan M
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Oct; 874(1-2):51-6. PubMed ID: 18824419
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The tyramine-labelled vesicular transporter for dopamine: a putative target of pesticides and neurotoxins.
    Vaccari A; Saba P
    Eur J Pharmacol; 1995 Mar; 292(3-4):309-14. PubMed ID: 7796871
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a neurochemical and morphological reassessment.
    Ricaurte GA; Langston JW; Delanney LE; Irwin I; Peroutka SJ; Forno LS
    Brain Res; 1986 Jun; 376(1):117-24. PubMed ID: 3487376
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine reduces the release of [3H]dopamine from rat striatal slices.
    Kurstjens NP; Cantrill RC
    Eur J Pharmacol; 1989 Oct; 169(1):147-52. PubMed ID: 2574687
    [TBL] [Abstract][Full Text] [Related]  

  • 49. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
    Muralikrishnan D; Samantaray S; Mohanakumar KP
    Synapse; 2003 Oct; 50(1):7-13. PubMed ID: 12872288
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of MPTP and its pyridinium metabolites on monoamine uptake and on central catecholamine neurons in mice.
    Jonsson G; Nwanze E; Luthman J; Sundström E
    Acta Physiol Scand; 1986 Oct; 128(2):187-94. PubMed ID: 3535380
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dopamine-releasing action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) in the neostriatum of the rat as demonstrated in vivo by the push-pull perfusion technique: dependence on sodium but not calcium ions.
    Sirinathsinghji DJ; Heavens RP; McBride CS
    Brain Res; 1988 Mar; 443(1-2):101-16. PubMed ID: 3258784
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lanthanides stimulate [3H]tyramine binding in the rat striatum.
    Vaccari A; Saba PL; Mocci I; Ruiu S
    Neurosci Lett; 1999 Feb; 261(1-2):49-52. PubMed ID: 10081924
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Monoamine oxidase inhibition by d-amphetamine in ganglia and nerve endings.
    Filinger EJ; Stefano FJ
    Experientia; 1982 Jul; 38(7):844-5. PubMed ID: 7106259
    [No Abstract]   [Full Text] [Related]  

  • 54. The tyramine binding site in the central nervous system: an overview.
    Vaccari A
    Neurochem Res; 1993 Aug; 18(8):861-8. PubMed ID: 8396735
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The colorful past and bright future of monoamine oxidase research.
    Singer TP
    Prog Brain Res; 1995; 106():1-22. PubMed ID: 8584646
    [No Abstract]   [Full Text] [Related]  

  • 56. Uptake of tritiated tyramine and (+) amphetamine by mouse heart slices.
    Ross SB; Renyi AL
    J Pharm Pharmacol; 1966 Nov; 18(11):756-7. PubMed ID: 4382056
    [No Abstract]   [Full Text] [Related]  

  • 57. Impact of Environmental Risk Factors on Mitochondrial Dysfunction, Neuroinflammation, Protein Misfolding, and Oxidative Stress in the Etiopathogenesis of Parkinson's Disease.
    Huang M; Bargues-Carot A; Riaz Z; Wickham H; Zenitsky G; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142718
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Striatal and urinary DOPAC/DA ratio may indicate a long-lasting DA release enhancement by MPP+ and MPTP.
    Bagchi SP
    Neurochem Res; 1998 Feb; 23(2):127-34. PubMed ID: 9475505
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High-affinity binding of [3H]1-methyl-4-phenyl-2,3-dihydropyridinium ion to mouse striatal membranes: putative vesicular location.
    Del Zompo M; Piccardi MP; Ruiu S; Corsini GU; Vaccari A
    Eur J Pharmacol; 1991 Sep; 202(2):293-4. PubMed ID: 1802748
    [No Abstract]   [Full Text] [Related]  

  • 60. The relative abilities of MPTP and MPP+ to compete with [3H]dopamine for the rat and marmoset striatal dopamine uptake site.
    Barnes NM; Cheng CH; Costall B; Naylor RJ
    Biochem Pharmacol; 1990 Feb; 39(4):809-11. PubMed ID: 2306287
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.